Sponsors (62)
The bill strengthens public safety and prosecutorial clarity by treating all fentanyl-related substances as a single, immediately enforceable class — improving deterrence and reducing new-analog circulation — but does so at the cost of higher research and administrative burdens, potential disruptions to legitimate medical access, expanded criminal exposure, and increased enforcement costs.
General public and communities: placing fentanyl-related substances in a class-wide Schedule I makes it easier for law enforcement to seize, remove, and prosecute novel fentanyl analogs, reducing the likelihood that Americans will encounter new, deadly variants on the street.
Law enforcement, courts, and regulators: clearer and consistent statutory definitions and corrected cross-references reduce legal uncertainty and litigation risk, enabling more uniform charging, prosecution, and adjudication of fentanyl-related offenses.
Researchers and health systems: provisions allowing limited research to start on a timetable (e.g., 30-day notice, 90-day continuation, single institutional registrations, incidental manufacturing) reduce abrupt interruptions to ongoing studies and administrative burdens for multi-site research.
Scientists, clinicians, and patients in need of new treatments: class-wide Schedule I designation substantially raises administrative and regulatory barriers to studying fentanyl-related compounds, delaying research and possible medical advances.
People charged with drug offenses and defendants generally: broader statutory definitions and immediate application expand criminal exposure and could subject individuals to harsher penalties — including for conduct that occurred before full implementing guidance was issued.
Patients who rely on legitimate opioid medications: supply or access could be disrupted if broad prosecution or supply-chain impacts constrain availability of needed medical products.
Based on analysis of 7 sections of legislative text.
Creates a broad Schedule I class for "fentanyl-related substances," updates definitions and penalties, and adds expedited registration rules for certain Schedule I research.
Creates a class-wide Schedule I rule that automatically places any compound meeting a broad structural definition of “fentanyl-related substance” into Schedule I, updates the statutory definition used across the Controlled Substances Act, and adjusts criminal penalty text accordingly. It also creates expedited registration and limited manufacturing/possession pathways for certain Schedule I research, requires DEA/HHS/DoD/VA coordination and an Inspector General report, and requires the Attorney General to issue implementing rules within six months that may take immediate effect as interim final rules. The measure aims to criminally control a wide range of fentanyl analogs while carving specific administrative processes to enable some research and institutional registration flexibility; it makes the scheduling changes effective on enactment and includes technical cross-reference fixes to earlier law.
Introduced January 3, 2025 by H. Morgan Griffith · Last progress February 10, 2025